Related Experiment Video
Updated: May 13, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Radiation-Activated Cobalt-Based Zeolite Imidazolate Frameworks for Tumor Multitherapy
Qijun Du1,2, Hongwei Jiang3, Di Wu1,2,4
1Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Abstract:
Radiation dynamic therapy (RDT) is known to induce cancer apoptosis and death with minimal side effects and high accuracy. However, low efficiency of radiation sensitization and persistent hypoxic environment in tumors pose marked challenges for successful RDT. To address these challenges, a novel biodegradable drug delivery system was developed, using quercetin and sorafenib-loaded ZIF67 nanoparticles (QSZP NPs) coated with polydopamine. This system effectively controlled the tumor microenvironment (TME), overcame hypoxia, and was thus utilized for collaborative RDT and radiotherapy (RT). The QSZP NPs demonstrated great potential in x-ray sensitization and reactive oxygen species (ROS)-mediated effects in vitro. Furthermore, they continuously generated oxygen and increased ROS levels in the TME with x-ray irradiation to achieve RDT. In vivo studies showed that QSZP NPs had no apparent systemic toxicity and showed good therapeutic effect in a HepG2 tumor-bearing model. Due to its unique and outstanding combinational effect of RDT/RT/antiangiogenic cancer therapy, these synthesized NPs offer a promising method for radiation-based cancer treatment.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy

